0001209191-24-001959.txt : 20240119
0001209191-24-001959.hdr.sgml : 20240119
20240119182535
ACCESSION NUMBER: 0001209191-24-001959
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240118
FILED AS OF DATE: 20240119
DATE AS OF CHANGE: 20240119
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Deignan Charles A.
CENTRAL INDEX KEY: 0001664690
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37783
FILM NUMBER: 24546666
MAIL ADDRESS:
STREET 1: C/O CLEARSIDE BIOMEDICAL, INC.
STREET 2: 1220 OLD ALPHARETTA ROAD, SUITE 300
CITY: ALPHARETTA
STATE: GA
ZIP: 30005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Clearside Biomedical, Inc.
CENTRAL INDEX KEY: 0001539029
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 452437375
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 900 NORTH POINT PARKWAY
STREET 2: SUITE 200
CITY: ALPHARETTA
STATE: GA
ZIP: 30005
BUSINESS PHONE: 678-270-3631
MAIL ADDRESS:
STREET 1: 900 NORTH POINT PARKWAY
STREET 2: SUITE 200
CITY: ALPHARETTA
STATE: GA
ZIP: 30005
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-01-18
0
0001539029
Clearside Biomedical, Inc.
CLSD
0001664690
Deignan Charles A.
C/O CLEARSIDE BIOMEDICAL, INC.
900 NORTH POINT PARKWAY, SUITE 200
ALPHARETTA
GA
30005
0
1
0
0
Chief Financial Officer
0
Common Stock
2024-01-19
4
S
0
12900
1.28
D
384662
D
Employee Stock Option (right to buy)
1.29
2024-01-18
4
A
0
200000
0.00
A
2034-01-18
Common Stock
200000
200000
D
The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.18 to $1.32 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
One-fourth of the shares underlying this option vest on January 18, 2025 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such vesting date.
/s/ Mark Ballantyne, Attorney-in-Fact
2024-01-19